|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
05.08.26 - 01:00
|
Mosaic (MOS) Q2 Earnings Top Estimates (Zacks)
|
|
|
Mosaic (MOS) delivered earnings and revenue surprises of +44.44% and -7.30%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?...
|
|
|
|
|
04.08.26 - 22:21
|
MOSAIC ANNOUNCES SECOND QUARTER 2026 RESULTS (PR Newswire)
|
|
|
TAMPA, Fla., Aug. 4, 2026 /PRNewswire/ -- The Mosaic Company (NYSE: MOS) released its financial results for the second quarter of 2026. The company's earnings release and supplemental materials are available at https://investors.mosaicco.com/financials/quarterly-results. Mosaic will host......
|
|
|
|
|
04.08.26 - 16:12
|
Mosaic Therapeutics ernennt Dr. Allison Jeynes zur Vorstandsvorsitzenden (Business Wire)
|
|
|
Die erfahrene Führungskraft aus dem Bereich Life Sciences, die sich durch die erfolgreiche Entwicklung neuartiger Therapeutika einen Namen gemacht hat, tritt bei Mosaic ein, um die nächste Wachstumsphase des Unternehmens zu leiten
Allison Jeynes bringt drei Jahrzehnte Erfahrung in der Arzneimittelentwicklung sowie in Führungspositionen im Vorstand und in der Geschäftsleitung mit, um den Übergang von Mosaic zu einem Unternehmen im klinischen Stadium zu unterstützen
CAMBRIDGE, England--(BUSINESS WIRE)--Mosaic Therapeutics, Ltd. („Mosaic“ oder „das Unternehmen“), ein Unternehmen für onkologische Therapeutika, das neuartige, zielgerichtete Wirkstoffkombinationen für eine Reihe von hämatologischen und soliden Krebserkrankungen entwickelt, gab heute die Ernennung von Dr. Allison Jeynes zur Vorstandsvorsitzenden bekannt, um die nächste Wachstumsphase und den Fortschritt in Richtung klinischer Entwicklung zu unterstützen. Allison tritt die Nachfolge von Dr. Edward Hodgkin an, der weiterhin als ...
|
|
|
04.08.26 - 09:03
|
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board (Business Wire)
|
|
|
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growth
Allison brings three decades of drug development, board and executive leadership experience to support Mosaic's transition towards a clinical-stage company
CAMBRIDGE, England--(BUSINESS WIRE)--Mosaic Therapeutics, Ltd, ('Mosaic', or 'the Company') an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board.
Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development compan...
|
|
|
|
|
|
|
|
|
|
|
|
|
15.07.26 - 22:24
|
MOSAIC ANNOUNCES SECOND QUARTER 2026 EARNINGS RESULTS DATES (PR Newswire)
|
|
|
TAMPA, Fla., July 15, 2026 /PRNewswire/ -- The Mosaic Company (NYSE: MOS) plans to release second quarter 2026 earnings results on Tuesday, August 4th, following the close of trading on the New York Stock Exchange. The company will issue a news wire alert when earnings materials are......
|
|
|
|